Global Community

Brava Energia looks like a troubled oil producer to the market, but its next few years could bring a big step-up in output and pricing power as new offshore wells come online and old contracts roll off. The key question is whether this expected turnaround arrives on schedule—and what could get in the way.Read more

Wall Street spent two years discovering that artificial intelligence needs electricity. Then Vistra fell from nearly $220 to $139 anyway.Read more

Accenture looks like a steady “workhorse” for big companies, but fears that AI could shrink consulting work have pushed investors away. The real question is whether Accenture can turn that AI disruption into a new wave of demand—or whether clients keep cutting back.Read more

Record revenue. Earnings up 83%.Read more

Cheetah Net shifts from a logistics and warehousing business into international trading after buying Super International Trading, and that new line could reshape what drives the company. The big question is whether it can integrate the deal and grow customers fast enough before cash needs or share issuance weigh on existing owners.Read more

Benz Mining’s Glenburgh project goes from a small, older estimate to a much bigger new target, and early drilling and test work point to pockets of higher-grade gold that could change the story. The catch is that the market already expects a lot, so the next round of drilling and a first official resource update will decide whether this is a breakout discovery or an overhyped one.Read more

Rezolve AI (NASDAQ: RZLV) is heading into its most consequential month since going public. Audited H1 2026 results land on the 1st of September, and court approval for the $300 million buyback and capital reduction is expected to follow within weeks.Read more

Unilever is reshaping itself by spinning off parts of its food business to put more attention on its biggest household and personal-care brands, and early signs suggest the leaner setup could run more efficiently. The big question is whether this shake-up can unlock steadier growth without giving up too much resilience—and what could go wrong if competition or deals don’t pan out.Read more

Zoetis sells medicines and diagnostics for pets and farm animals, and it benefits from long-term trends like people spending more on their animals and wider use of pet insurance. The key question is whether today’s share price leaves enough room for those tailwinds—or whether you should wait for a better entry given competition, regulation, and currency swings.Read more